Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBS104
- Development stage
- Preclinical
- Lead developer
- CellmAbs
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
CBS104 is a preclinical-stage monoclonal antibody developed by CellmAbs, a biotechnology company specializing in glyco-oncology. The antibody is designed to target cancer-specific glycans, which are carbohydrate modifications on proteins or lipids that are uniquely or over-expressed on tumor cells. By specifically recognizing these tumor-associated glycan antigens, CBS104 is intended to selectively target cancer cells while sparing healthy tissue. As of the current pipeline information, the specific glycan target for CBS104 remains undisclosed, and the program is in the preclinical phase of development for oncology indications.
- Other names
- CBS-104CBS104CBS 104
Beyond the preview
Go deeper on CBS104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBS104.